Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial

World Journal of Gastroenterology

Volumn 10, Issue 1, 2004, Pages 136-142

  Lin, Cong Yao ^a   Bai, De Jiao ^a   Yuan, Hong Yin ^a   Wang, Kun ^a   Yang, Guo Liang ^a   Hu, Ming Bai ^a   Wu, Zhou Qing ^a   Li, Yan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD57 ANTIGEN; CIMETIDINE; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; OKT 8;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER GROWTH; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; FEMALE; HELPER CELL; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; MALE; NATURAL KILLER CELL; PERIOPERATIVE PERIOD; PERIPHERAL CIRCULATION; PERIPHERAL LYMPHOCYTE; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; STOMACH CANCER; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0347946704     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i1.136     Document Type: Article

References (61)

1. Yip D, Strickland AH, Karapetis CS, Hawkins CA, Harper PG. Immunomodulation therapy in colorectal carcinoma. Cancer Treat Rev 2000; 26: 169-190
2. Weiss G, Meyer F, Matthies B, Pross M, Koenig W, Lipper H. Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr 2002; 87 (Suppl 1): S89-94
3. Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, Takekawa M, Ando K, Fukuzawa M. Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 2002; 20: 166-173
4. Wu GH, Zhang YW, Wu ZH. Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients. World J Gastroenterol 2001; 7: 357-362
5. Tayama E, Hayashida N, Fukunaga S, Tayama K, Takaseya T, Hiratsuka R, Aoyagi S. High-dose cimetidine reduces proinflammatory reaction after cardiac surgery with cardiopulmonary bypass. Ann Thorac Surg 2001; 72: 1945-1949
6. Bai DJ, Yang GL, Yuan HY, Li Y, Wang K. Effects of cimetidine on T lymphocyte subsets in perioperative gastrointestinal cancer patients. Shijie Huaren Xiaohua Zazhi 2000; 8: 147-149
7. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet 1994; 344: 1768-1769
8. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet 1995; 346: 115
9. Svendsen LB, Ross C, Knigge U, Frederiksen HJ, Graversen P, Kjaergard J, Luke M, Stimpel H, Sparso BH. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum 1995; 38: 514-518
10. Hellstrand K, Naredi P, Lindner P, Lundholm K, Rudenstam CM, Hermodsson S, Asztely M, Hafstrom L. Histamine in immunotherapy of advanced melanoma: A pilot study. Cancer Immunol Immunother 1994; 39: 416-419
11. Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, Itri LM. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 1985; 3: 977-981
12. Sagaster P, Micksche M, Flamm J, Ludwig H. Randomised study using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 1995; 6: 999-1003
13. Morris DL, Adams WJ. Cimetidine and colorectal cancer-old drug, new use? Nat Med 1995; 1: 1243-1244
14. Sasson AR, Gamagami R, An Z, Wang X, Moossa AR, Hoffman RM. Cimetidine: An inhibitor or promoter of tumor growth? Int J Cancer 1999; 81: 835-838
15. Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, King DW, Lubowski DZ, Morris DL. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer 1999; 85: 1658-1663
16. Hansbrough JF, Zapata-Sirvent RL, Bender EM. Prevention of alterations in postoperative lymphocyte subpopulations by cimetidine and ibuprofen. Am J Surg 1986; 151: 249-255
17. Adams WJ, Morris DL, Ross WR, Lubowski DZ, King DW, Peters L. Cimetidine preserves non-specific immune function after colonic resection for cancer. Aust N Z J Surg 1994; 64: 847-852
18. Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994; 35: 1632-1636
19. Lawson JA, Adams WJ, Morris DL. Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Br J Cancer 1996; 73: 872-876
20. Reynolds JL, Akhter J, Morris DL. In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines. Melanoma Res 1996; 6: 95-99
21. Jass JR, Ajioka Y, Allen JP, Chan YF, Cohen RJ, Nixon JM, Radojkovic M, Restall AP, Stables SR, Zwi LJ. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 1996; 28: 543-548
22. Hansbrough JF, Bender EM, Zapata-Sirvent R, Anderson J. Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression. Am J Surg 1984; 148: 303-307
23. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992; 52: 5765-5769
24. Espi A, Arenas J, Garcia-Granero E, Marti E, Lledo S. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Dis Colon Rectum 1996; 39: 429-434
25. Leaver HA, Craig SR, Yap PL, Walker WS. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest 2000; 30: 230-238
26. van Sandick JW, Gisbertz SS, ten Berge IJ, Boermeester MA, van der Pouw Kraan TC, Out TA, Obertop H, van Lanschot JJ. Immune responses and prediction of major infection in patients undergoing transhiatal or transthoracic esophagectomy for cancer. Ann Surg 2003; 237: 34-43
27. Sato N, Endo S, Kimura Y, Ikeda K, Aoki K, Iwaya T, Akiyama Y, Noda Y, Saito K. Influence of a human protease inhibitor on surgical stress induced immunosupression. Dig Surg 2002; 19: 300-305
28. Yao XX, Yin L, Sun ZC. The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis. World J Gastroenterol 2002; 8: 586-590
29. Braga M, Vignali A, Zuliani W, Radaelli G, Gianotti L, Martani C, Toussoun G, Di Carlo V. Metabolic and functional results after laparoscopic colorectal surgery: A randomized, controlled trial. Dis Colon Rectum 2002; 45: 1070-1077
30. Wang YX, Ruan CP, Li L, Shi JH, Kong XT. Clinical significance of changes of perioperative T cell and expression of its activated antigen in colorectal cancer patients. World J Gastroenterol 1999; 5: 181-182
31. Yuan HY, Li Y, Yang GL, Bei DJ, Wang K. Study on the causes of local recurrence of rectal cancer after curative resection: Analysis of 213 cases. World J Gastroenterol 1998; 4: 527-529
32. Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 1993; 71(12 Suppl): 4252-4266
33. Vaughn D, Haller DG. Nonsurgical management of recurrent colorectal cancer. Cancer 1993; 71: 4278-4292
34. Turk PS, Wanebo HJ. Results of surgical treatment of nonhepatic recurrence of colorectal carcinoma. Cancer 1993; 71(12 Suppl): 4267-4277
35. Beer DJ, Rocklin RE. Histamine-induced suppressor-cell activity. J Allergy Clin Immunol 1984; 73: 439-452
36. Lima M, Rocklin RE. Histamine modulates in vitro IgG production by pokeweed mitogen-stimulated human mononuclear cells. Cell Immunol 1981; 64: 324-336
37. Rocklin RE, Blidy A, Kamal M. Physiochemical characterization of human histamine-induced suppressor factor. Cell Immunol 1983; 76: 243-252
38. Uotila P. Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy. Cancer Immunol Immunother 1993; 37: 251-254
39. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385-390
40. Melmon KL, Bourne HR, Weinstein J, Sela M. Receptors for histamine can be detected on the surface of selected leukocytes. Science 1972; 177: 707-709
41. 2 receptors from calf thymocyte membranes. J Biol Chem 1979; 254: 9970-9972
42. 2 histamine receptors. Br J Cancer 1982; 45: 54-60
43. Rocklin RE, Greineder DK, Melmon KL. Histamine-induced suppressor factor (HSF): Further studies on the nature of the stimulus and the cell which produces it. Cell Immunol 1979; 44: 404-415
44. Adams WJ, Lawson JA, Nicholson SE, Cook TA, Morris DL. The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol 1993; 19: 332-335
45. Nishiguchi S, Tamori A, Shiomi S, Enomoto M, Tatsumi N, Koh N, Habu D, Sakaguchi H, Takeda T, Seki S, Nakamura K, Kubo S, Kinoshita H. Cimetidine reduces impairment of cellular immunity after transcatheter arterial embolization in patients with hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 460-462
46. Zhu Q, Si F, Xu JY, Wu YL. Effect of cimetidine against digestive tract tumors. Huaren Xiaohua Zazhi 1998; 6: 68-69
47. Bobek V, Boubelik M, Kovarik J, Taltynov O. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine. Neoplasma 2003; 50: 148-151
48. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res 2000; 60: 3978-3984
49. Takahashi K, Tanaka S, Ichikawa A. Effect of cimetidine on intratumoral cytokine expression in an experimental tumor. Biochem Biophys Res Commun 2001; 281: 1113-1119
50. Szincsak N, Hegyesi H, Hunyadi J, Falus A, Juhasz I. Different h2 receptor antihistamine dissimilarly retard the growth of xenografted human melanoma cells in immunodeficient mice. Cell Biol Int 2002; 26: 833-836
51. Szincsak N, Hegyesi H, Hunyadi J, Martin G, Lazar-Molnar E, Kovacs P, Rivera E, Falus A, Juhasz I. Cimetidine and a tamoxifen derivative reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line. Melanoma Res 2002; 12: 231-240
52. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321
53. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384
54. Wang XZ, Li B, Zheng XX, Qu YZ, Lin GZ, Tang NH, Chen ZX. Experimental and clinical study on tumor infiltrating lymphocytes in solid tumor. Xin Xiaohuabingxue Zazhi 1997; 5: 481-482
55. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S., Labarriere N, Jotereau F. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002; 51: 539-546
56. Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B, Jotereau F. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002; 51: 532-538
57. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial. Clin Cancer Res 2002; 8: 1767-1771
58. Liu SC, Yuan SZ. Relationship between infiltration of dendritic cells, pericancerous lymphocytic reaction and prognosis in colorectal carcinomas. Xin Xiaohuabingxue Zazhi 1997; 5: 156-157
59. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854
60. Kubota T, Fujiwara H, Ueda Y, Itoh T, Yamashita T, Yoshimura T, Okugawa K, Yamamoto Y, Yano Y, Yamagishi H. Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients. Br J Cancer 2002; 86: 1257-1261
61. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 2002; 86: 161-167